Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scan study aims to unlock Glaucoma's secrets

NCT ID NCT06274593

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 50 people with advanced glaucoma for three years, using a special eye scan (OCT angiography) to measure blood flow around the optic nerve. Researchers want to see how these scans compare with standard vision tests in tracking the disease. The goal is to better understand how glaucoma damages eyesight over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict how glaucoma progresses by using a non-invasive imaging test.
What could go wrong
This is a small, observational study with only 50 participants, so results may not apply to everyone. It is not testing a treatment, so it won't directly improve vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients followed at Nantes University Hospital for advanced glaucoma (MD\>10dB in visual field) who had peripapillary angiography OCT, OCTrnfl and visual field at their follow-up consultation.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 18 and over * Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital * mean visual field deficit (MD) \>10dB Exclusion Criteria: * Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) * PPR (retinal PanPhotocoagulation), retinal cerclage * Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) * AMD and other macular pathologies that can lead to central visual field deficits * Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) * Loss of fixation point preventing visual field formation Pregnant or breast-feeding women * Protected adults under guardianship or curatorship * with unreliable visual fields (false positives and false negatives \> 33%) * with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Nantes

    RECRUITING

    Nantes, Nantes, 44000, France

  • Jean-Baptiste Ducloyer

    NOT_YET_RECRUITING

    Nantes, Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.